LB Pharmaceuticals Inc.
LB Pharmaceuticals Inc. is listed today as LB Pharmaceuticals Inc: market value, financials and filings are on its company page.
Funding rounds
2 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Aug 2023 | $111 M | No. 2 | $50 to $250 million | equity, options | SEC | |
| Nov 2018 | $6 M | No. 1 | $2 to $10 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
LB Pharmaceuticals Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2024).
SEC Form D · Jan 2024
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Jan 2024
That is all the official record says: LB Pharmaceuticals Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of LB Pharmaceuticals Inc. are on record.
Investors#
6 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Deep Track Biotechnology Master Fund, Ltd. | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2025) | SEC Form 3 |
| Deep Track Capital, LP | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2025) | SEC Form 3 |
| Pontifax Management 4 G.P. (2015) Ltd. | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2025) | SEC Form 3 |
| Vida Ventures GP III, L.L.C. | Venture capital | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2025) | SEC Form 3 |
| Vida Ventures III-A, L.P. | Venture capital | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2025) | SEC Form 3 |
| Vida Ventures III, L.P. | Venture capital | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2025) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 74 investors.
Largest shareholders today
Institutions holding LB Pharmaceuticals Inc shares, as of Sep 30, 2026.
- Deep Track Capital, LP$129 M10.36%
- BlackRock, Inc.$90 M7.25%
- Ra Capital Management, L.P.$85 M6.82%
- Caligan Partners LP$58 M4.66%
- Jpmorgan Chase & Co$55 M4.46%
- Spruce Street Capital LP$54 M4.34%
- Commodore Capital LP$49 M3.96%
- Trails Edge Capital Partners, LP$44 M3.55%
- FMR LLC$42 M3.41%
- Vanguard Capital Management LLC$42 M3.40%
- Nantahala Capital Management, LLC$41 M3.32%
- Goldman Sachs Group Inc$37 M2.98%
- Adage Capital Partners GP, L.L.C.$36 M2.94%
- Balyasny Asset Management L.P.$31 M2.48%
- Vivo Capital, LLC$31 M2.47%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Andrew Vaino | Executive officer | Jan 2024 |
| Anna Eramo | Executive officer | Jan 2024 |
| Marc Panoff | Executive officer | Jan 2024 |
| Zachary Prensky | Executive officer | Jan 2024 |
| Chen Yu | Director | Jan 2024 |
| Rajul Jain | Director | Jan 2024 |
| Ran Nussbaum | Director | Jan 2024 |
| Rebecca Luse | Director | Jan 2024 |
| Robert Ruffolo | Director | Jan 2024 |
| Zachary Prensky | Director | Jan 2024 |
| Simon Basseyn | Director | Sep 2023 |
| Edmund Sullivan | Director | Dec 2018 |
| Vincent Grattan | Director | Dec 2018 |
Went public since 2025. Its SEC number is that of a company listed on a stock exchange.